Gillian Cannon

Gillian Cannon

Director/Board Member at XENON PHARMACEUTICALS INC.

Net worth: 87 824 $ as of 29/06/2026

62 year
Health Technology
Consumer Services
Finance

Profile

Gillian M.
Cannon
is currently Director at Affibody AB since 2019, Independent Director at Xenon Pharmaceuticals, Inc. since 2023, and Director at Edinburgh Innovations Ltd. since 2020.
Former roles include Independent Director at Corcept Therapeutics, Inc. from 2020 to 2025, President-North American Operations at UCB, Inc. from 2015 to 2017, Vice President-Commercial Operations at Merck BioVentures from 2008 to 2012, President at Alyvant, Inc., and Head-Commercial Innovation at Roivant Sciences, Inc. from 2020 to 2024.
Education includes undergraduate studies at The University of Edinburgh and doctorates from Temple University (Pennsylvania) and Fox School of Business.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
04/06/2026 1,455 ( 0% ) 87 824 $ 29/06/2026
09/09/2025 0 ( -.--% ) - $ 29/06/2026

Gillian Cannon active positions

CompaniesPositionStart
XENON PHARMACEUTICALS INC. Director/Board Member 07/08/2023
Director/Board Member 31/12/2018
Director/Board Member 31/12/2019

Former positions of Gillian Cannon

CompaniesPositionEnd
CORCEPT THERAPEUTICS INCORPORATED Director/Board Member 09/10/2025
Corporate Officer/Principal 31/03/2024
Corporate Officer/Principal 31/12/2016
Merck BioVentures
Corporate Officer/Principal 31/12/2011
President -
See the detail of Gillian Cannon's experience

Training of Gillian Cannon

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

18

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Finance

Commercial Services

Consumer Services

Merck BioVentures

Health Technology

  1. Stock Market
  2. Insiders
  3. Gillian Cannon